BRIEF-FDA grants Merrimack fast track designation for Seribantumab (mm-121) in non-small cell lung cancer
…
Seribantumab (Mm-121) in non-small cell lungcancer
* FDA grants Merrimack fast track …
seribantumab (mm-121) in non-small cell lungcancer
* Merrimack is investigating efficacy and …
No comments:
Post a Comment